GB201202027D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB201202027D0
GB201202027D0 GBGB1202027.7A GB201202027A GB201202027D0 GB 201202027 D0 GB201202027 D0 GB 201202027D0 GB 201202027 A GB201202027 A GB 201202027A GB 201202027 D0 GB201202027 D0 GB 201202027D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1202027.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Priority to GBGB1202027.7A priority Critical patent/GB201202027D0/en
Publication of GB201202027D0 publication Critical patent/GB201202027D0/en
Priority to BR112014019254-5A priority patent/BR112014019254B1/pt
Priority to HK15104909.5A priority patent/HK1204327B/en
Priority to AU2013218167A priority patent/AU2013218167B2/en
Priority to US14/376,729 priority patent/US9133180B2/en
Priority to KR1020147024086A priority patent/KR102052780B1/ko
Priority to RU2014131784A priority patent/RU2643809C2/ru
Priority to CA2863759A priority patent/CA2863759C/en
Priority to PCT/EP2013/052182 priority patent/WO2013117522A1/en
Priority to CN201380013544.5A priority patent/CN104169277B/zh
Priority to SG11201404277WA priority patent/SG11201404277WA/en
Priority to DK13702642.3T priority patent/DK2812328T3/en
Priority to JP2014555250A priority patent/JP6034880B2/ja
Priority to EP13702642.3A priority patent/EP2812328B1/en
Priority to ES13702642.3T priority patent/ES2560260T3/es
Priority to PT137026423T priority patent/PT2812328E/pt
Priority to MX2014009323A priority patent/MX338481B/es
Priority to PL13702642T priority patent/PL2812328T3/pl
Priority to IL233988A priority patent/IL233988A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1202027.7A 2012-02-06 2012-02-06 Pharmaceutical compounds Ceased GB201202027D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds
PL13702642T PL2812328T3 (pl) 2012-02-06 2013-02-04 Modulatory kinaz Aurora i FLT3
PCT/EP2013/052182 WO2013117522A1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators
SG11201404277WA SG11201404277WA (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators
AU2013218167A AU2013218167B2 (en) 2012-02-06 2013-02-04 Aurora and FLT3 kinases modulators
US14/376,729 US9133180B2 (en) 2012-02-06 2013-02-04 Aurora and FLT3 kinases modulators
KR1020147024086A KR102052780B1 (ko) 2012-02-06 2013-02-04 오로라 및 flt3 키나제 조절자
RU2014131784A RU2643809C2 (ru) 2012-02-06 2013-02-04 Модуляторы киназ aurora и flt3
CA2863759A CA2863759C (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators
BR112014019254-5A BR112014019254B1 (pt) 2012-02-06 2013-02-04 Compostos moduladores de aurora e flt3 quinases e composições contendo os mesmos
CN201380013544.5A CN104169277B (zh) 2012-02-06 2013-02-04 极光激酶和flt3激酶调节剂
HK15104909.5A HK1204327B (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators
DK13702642.3T DK2812328T3 (en) 2012-02-06 2013-02-04 Aurora AND FLT3-KINASEMODULATORER
JP2014555250A JP6034880B2 (ja) 2012-02-06 2013-02-04 オーロラおよびｆｌｔ３キナーゼモジュレーター
EP13702642.3A EP2812328B1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators
ES13702642.3T ES2560260T3 (es) 2012-02-06 2013-02-04 Moduladores de Aurora y FLT3 quinasas
PT137026423T PT2812328E (pt) 2012-02-06 2013-02-04 Moduladores de aurora e flt3 quinases
MX2014009323A MX338481B (es) 2012-02-06 2013-02-04 Moduladores de quinasas de aurora y flt3.
IL233988A IL233988A (en) 2012-02-06 2014-08-05 Aurora kinase and flt3 kinase modulators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB201202027D0 true GB201202027D0 (en) 2012-03-21

Family

ID=45896692

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1202027.7A Ceased GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds

Country Status (18)

Country Link
US (1) US9133180B2 (enExample)
EP (1) EP2812328B1 (enExample)
JP (1) JP6034880B2 (enExample)
KR (1) KR102052780B1 (enExample)
CN (1) CN104169277B (enExample)
AU (1) AU2013218167B2 (enExample)
BR (1) BR112014019254B1 (enExample)
CA (1) CA2863759C (enExample)
DK (1) DK2812328T3 (enExample)
ES (1) ES2560260T3 (enExample)
GB (1) GB201202027D0 (enExample)
IL (1) IL233988A (enExample)
MX (1) MX338481B (enExample)
PL (1) PL2812328T3 (enExample)
PT (1) PT2812328E (enExample)
RU (1) RU2643809C2 (enExample)
SG (1) SG11201404277WA (enExample)
WO (1) WO2013117522A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522968B2 (ja) 1987-10-23 1996-08-07 尾池工業株式会社 印刷回路転写箔およびその製造法
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JPH06310767A (ja) 1993-04-26 1994-11-04 Nec Corp 寒剤容器の断熱支持構造
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
AU2003902208A0 (en) * 2003-05-08 2003-05-22 Fujisawa Pharmaceutical Co., Ltd. Inhibitor of cox
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
KR101792651B1 (ko) * 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP2320293A1 (en) * 2009-11-05 2011-05-11 Koninklijke Philips Electronics N.V. Sleep element for improving the sleep of a person
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
ES2566205T3 (es) 2012-03-02 2016-04-11 Sareum Limited Inhibidores de quinasa TYK2

Also Published As

Publication number Publication date
CN104169277B (zh) 2016-10-12
MX338481B (es) 2016-04-19
SG11201404277WA (en) 2014-08-28
DK2812328T3 (en) 2016-01-11
BR112014019254A8 (pt) 2017-07-11
IL233988A (en) 2017-06-29
RU2014131784A (ru) 2016-03-27
CN104169277A (zh) 2014-11-26
PL2812328T3 (pl) 2016-04-29
JP2015511228A (ja) 2015-04-16
RU2643809C2 (ru) 2018-02-06
AU2013218167B2 (en) 2017-04-06
BR112014019254B1 (pt) 2020-03-10
US20150018367A1 (en) 2015-01-15
US9133180B2 (en) 2015-09-15
CA2863759C (en) 2020-04-14
WO2013117522A1 (en) 2013-08-15
CA2863759A1 (en) 2013-08-15
EP2812328A1 (en) 2014-12-17
JP6034880B2 (ja) 2016-11-30
PT2812328E (pt) 2016-03-01
HK1204327A1 (en) 2015-11-13
BR112014019254A2 (enExample) 2017-06-20
KR20140128373A (ko) 2014-11-05
AU2013218167A1 (en) 2014-08-14
MX2014009323A (es) 2015-04-08
ES2560260T3 (es) 2016-02-18
EP2812328B1 (en) 2015-11-18
KR102052780B1 (ko) 2019-12-05

Similar Documents

Publication Publication Date Title
AP2014007810A0 (en) Imidazopyrrolidinone compounds
PL2776416T3 (pl) Związki farmaceutyczne
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
GB201214750D0 (en) Compounds
ZA201501930B (en) Pharmaceutical composition
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
GB201204125D0 (en) Compounds
GB201119799D0 (en) Pharmaceutical compounds
GB201209096D0 (en) Compounds
ZA201403832B (en) Pharmaceutical compounds
GB201205164D0 (en) Pharmaceutical compounds
GB201118876D0 (en) Pharmaceutical compounds
GB201113163D0 (en) Pharmaceutical compounds
HUE037618T2 (hu) Gyógyszerészeti kombinációk
IL239512A0 (en) Pharmaceutical compounds
ZA201502987B (en) Pharmaceutical composition
GB201217310D0 (en) Compounds
GB201305860D0 (en) Pro-Pos
GB201219236D0 (en) Pharmaceutical compounds
GB201214121D0 (en) Pharmaceutical compounds
GB201213519D0 (en) Pharmaceutical compounds
GB201203253D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)